# SOC-1 (NCT01611766)

> Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)?

No report yet. It can be ordered.

- Drugs tested: none (the trial tests a strategy, not a drug)
- Indication: platinum-sensitive relapsed ovarian cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01611766
- Phase: PHASE3
- Status: UNKNOWN
- Sponsor: Shanghai Gynecologic Oncology Group
- Conditions: Ovarian Epithelial Cancer Recurrent; Fallopian Tube Carcinoma; Primary Peritoneal Carcinoma
- Interventions: Secondary Cytoreductive Surgery; Salvage Chemotherapy
- Enrollment: 356
- Primary outcome: Overall survival
- Primary outcome: Progression-free survival

## Indexed commentary on SOC-1 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 10 posts on X
- 5 podcast episodes
- 2 YouTube videos

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=soc-1-nct01611766

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01611766", "email": "<work email>"}; the inbox owner confirms by the emailed link.